Our Solution
Introducing LisenID: The Future of Cancer Diagnosis
We have developed the first molecular diagnostics test and platform that uses the Loss of Imprinting biomarker–one of the earliest indicators to carcinogenesis–and AI to visually identify carcinogenesis and predict cancer in routine tumor biopsy samples, with up to 95% accuracy.
OUR INITIAL FOCUS
Clear. Accurate. Early. Actionable.
Diagnosis for Lung Cancer
Utilizing Lavage & TBNA Samples
diagnosis for Breast cancer
Utilizing CNB & FNA Samples
Diagnosis for Skin Cancer
Utilizing Skin Biopsy Samples
Where Traditional Diagnosis Fails
About us
Leading the Future of Early Cancer Detection
25+
Team
Memebers
Patents Achieved
Case Studies
Cancer Types Tested
High-Impact Publications
TEAM MEMBER
AWARD WINNING TEAM
Dr. Ning Zhou
Co-Founder and Chairman
Dr.Tina Cheng
Co-Founder and CTO
Hannah Zhou,
Partner & CEO
OUR BENEFITS
OUR ADVANTAGE
Early-Stage Detection
High Accuracy
Clinical Confidence
Seamless Workflow Integration
Scalable Growth
Strong IP & Validation
12 granted patents, supported by top-tier journal publications.
1500+
Projects done
Case Studies
Novel visualized quantitative epigenetic imprinted gene biomarkers diagnose the malignancy of ten cancer types
Novel visualized quantitative epigenetic imprinted gene biomarkers diagnose the malignancy of ten cancer types.
Epigenetic imprinting alterations as effective diagnostic biomarkers for early-stage lung cancer and small pulmonary nodules
Epigenetic imprinting alterations as effective diagnostic biomarkers for early-stage lung cancer and small pulmonary nodules.
High Diagnostic Accuracy of Epigenetic Imprinting Biomarkers in Thyroid Nodules
High diagnostic accuracy of epigenetic imprinting biomarkers in thyroid nodules.
Genomic imprinting biomarkers for cervical cancer risk stratification
Genomic imprinting biomarkers for cervical cancer risk stratification.
Hear from our Co-Founder & CTO
Dr. Tina Cheng
Existing molecular tests that rely on circulating tumor DNA, DNA methylation, or complex genomic panels rely on later stage cancer development that sacrifices accuracy for convenience, are influenced by intense noise leading to inconsistent results, or too costly to patients. All of which lead to delayed treatment, worse patient outcomes, repeated and follow-up tests, and rising costs.